SEC Comment Letter 0000000000-23-006475 to Pyxis Oncology, Inc. (PYXS) (CIK 0001782223) (PYXS)
Pyxis Oncology, Inc. (PYXS) (CIK 0001782223)
Date: June 15, 2023 · CIK: 0001782223 · Accession: 0000000000-23-006475
AI Filing Summary & Sentiment
File numbers found in text: 333-272510
Letter
United States securities and exchange commission logo June 15, 2023 Lara Sullivan, M.D. Chief Executive Officer Pyxis Oncology, Inc. 321 Harrison Avenue Boston, MA 02118 Re:Pyxis Oncology, Inc. Registration Statement on Form S-4 Filed June 8, 2023 File No. 333-272510 Dear Lara Sullivan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Istvan A. Hajdu
Show Raw Text
United States securities and exchange commission logo
June 15, 2023
Lara Sullivan, M.D.
Chief Executive Officer
Pyxis Oncology, Inc.
321 Harrison Avenue
Boston, MA 02118
Re:Pyxis Oncology, Inc.
Registration Statement on Form S-4
Filed June 8, 2023
File No. 333-272510
Dear Lara Sullivan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Istvan A. Hajdu